Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 02, 2019 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

NEWARK, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
November 20, 2018 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Participate in Upcoming Investor Conferences

NEWARK, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
November 13, 2018 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Presents Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC at The Liver Meeting® 2018

Sustained anti-cholestatic and anti-inflammatory effects observed with no worsening of pruritus through 52 weeks Results highlight the potential for seladelpar to offer patients an efficacious and...
November 06, 2018 16:10 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports Third Quarter 2018 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused on...
October 30, 2018 16:05 ET | Source: CymaBay Therapeutics, Inc.

CymaBay to Report Third Quarter 2018 Financial Results on Tuesday, November 6

NEWARK, Calif., Oct. 30, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
October 30, 2018 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Announces the Initiation of the Seladelpar Global Phase 3 Registration Study (ENHANCE) for the Treatment of Primary Biliary Cholangitis and Additional Corporate Updates

Phase 3 patient enrollment commenced with multiple investigational sites in the U.S. initiatedTeam expanded with key hires focused on delivering a high-quality registration package NEWARK, Calif.,...
October 03, 2018 09:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics Announces Additional Positive Results from its Ongoing Phase 2 Study of Seladelpar in Patients with PBC will be Presented During the Late-Breaking Session at The Liver Meeting®

52-week analysis highlights the potential for seladelpar to offer patients improved efficacy and better tolerability than existing second line treatmentThird consecutive year data from the development...
September 24, 2018 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Participate in Upcoming Investor Conferences in October

NEWARK, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
August 14, 2018 08:00 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Therapeutics to Participate in Upcoming Investor Conferences in August and September

NEWARK, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...
August 09, 2018 16:01 ET | Source: CymaBay Therapeutics, Inc.

CymaBay Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY) a clinical-stage biopharmaceutical company focused on...